Predict your next investment

Venture Capital
baycitycapital.com

See what CB Insights has to offer

Investments

185

Portfolio Exits

63

Funds

9

Partners & Customers

1

About Bay City Capital

Bay City Capital is a life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing. Its investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of our partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members.

Bay City Capital Headquarter Location

750 Battery Street Suite 400

San Francisco, California, 94111,

United States

415-676-3830

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Bay City Capital News

Oculis Closes US$57M Series C Financing

May 5, 2021

Oculis S.A. , a Lausanne, Switzerland-based late-stage biopharmaceutical company focused on developing ophthalmic treatments to improve the sight and lives of patients, closed a US$57m Series C financing. The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg, as well as other existing investors. Led by Riad Sherif, MD, CEO, Oculis is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients. Proceeds from this financing will advance the company’s late-stage topical Ophthalmic portfolio, including: – Moving OCS-01 into Phase 3 trials in Diabetic Macular Edema (DME) and complete registration studies in the treatment of Inflammation and Pain following Ocular Surgery. – Advancing OCS-02 into Phase 2b trials targeting Dry Eye Disease (DED) and Chronic Anterior Uveitis as a steroid-sparing treatment. OCS-02 is a novel topical anti-TNF alpha antibody fragment, which has demonstrated efficacy and safety in two clinical proof of concept studies in moderate-to-severe DED and Acute Anterior Uveitis. In conjunction with the closing, Vanessa Huang, General Partner at BVCF Management, and Dr. Sylvia He, Managing Partner at Hyfinity Investments are joining the Oculis Board of Directors while Dr. David Weber and Dr. Thorsteinn Loftsson are stepping down. FinSMEs 06/05/2021

Bay City Capital Investments

185 Investments

Bay City Capital has made 185 investments. Their latest investment was in Oculis as part of their Series C on May 5, 2021.

CBI Logo

Bay City Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/5/2021

Series C

Oculis

$57M

No

12

3/2/2020

Series B

Xilio Therapeutics

$100.5M

Yes

7

3/18/2019

Series B

Imara

$63M

No

5

1/4/2019

Unattributed VC

Subscribe to see more

Subscribe to see more

10

1/4/2019

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/5/2021

3/2/2020

3/18/2019

1/4/2019

1/4/2019

Round

Series C

Series B

Series B

Unattributed VC

Series B - II

Company

Oculis

Xilio Therapeutics

Imara

Subscribe to see more

Subscribe to see more

Amount

$57M

$100.5M

$63M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

12

7

5

10

10

Bay City Capital Portfolio Exits

63 Portfolio Exits

Bay City Capital has 63 portfolio exits. Their latest portfolio exit was Xilio Therapeutics on October 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/22/2021

IPO

$99M

Public

10

3/12/2020

IPO

$99M

Public

1

1/7/2020

Merger

$99M

2

10/14/2019

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

5/9/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/22/2021

3/12/2020

1/7/2020

10/14/2019

5/9/2019

Exit

IPO

IPO

Merger

Acq - P2P

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

10

1

2

10

10

Bay City Capital Fund History

9 Fund Histories

Bay City Capital has 9 funds, including Bay City Bridge LLC.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/13/2018

Bay City Bridge LLC

Multi-Stage Venture Capital

Closed

$2M

1

10/25/2007

Bay City Capital Fund V LP

Subscribe to see more

Subscribe to see more

$99M

10

11/22/2005

Bay City Capital Fund IV LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2000

Bay City Capital Fund III LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/1999

North American Nutrition and Agribusiness Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

2/13/2018

10/25/2007

11/22/2005

12/31/2000

12/31/1999

Fund

Bay City Bridge LLC

Bay City Capital Fund V LP

Bay City Capital Fund IV LP

Bay City Capital Fund III LP

North American Nutrition and Agribusiness Fund

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Bay City Capital Partners & Customers

1 Partners and customers

Bay City Capital has 1 strategic partners and customers. Bay City Capital recently partnered with Takeda Pharmaceutical on November 11, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

11/9/2016

Partner

Japan

Bay City Capital Partners with TDI, Takeda and Deerfield Management to Launch Bridge Medicines

Launched in partnership with Takeda and healthcare investment firms Bay City Capital LLC and Deerfield Management , Bridge Medicines is a groundbreaking initiative that completes a seamless , fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases .

1

Date

11/9/2016

Type

Partner

Business Partner

Country

Japan

News Snippet

Bay City Capital Partners with TDI, Takeda and Deerfield Management to Launch Bridge Medicines

Launched in partnership with Takeda and healthcare investment firms Bay City Capital LLC and Deerfield Management , Bridge Medicines is a groundbreaking initiative that completes a seamless , fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases .

Sources

1

Bay City Capital Team

19 Team Members

Bay City Capital has 19 team members, including current Founder, Managing Director, Fred Craves.

Name

Work History

Title

Status

Fred Craves

Founder, Managing Director

Current

Susan Vuong

Chief Financial Officer

Current

David Beier

Managing Director

Current

Lionel Carnot

Managing Director

Current

Lionel Carnot

Managing Director

Current

Name

Fred Craves

Susan Vuong

David Beier

Lionel Carnot

Lionel Carnot

Work History

Title

Founder, Managing Director

Chief Financial Officer

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.